onstrated no difference in mortality between the albumin and saline groups (3). In the absence of a survival benefit, the clinical value of albumin infusion might be questioned. However, the effects of albumin on other clinically relevant endpoints, such as morbidity, need to be considered.
The incidence of death in broad populations of acutely ill patients is 10% to 17% (1, 2), and consequently, mortality is a comparatively insensitive endpoint. The frequency of complications, by contrast, is generally far higher than that of deaths, and thus, morbidity might afford a more sensitive endpoint for metaanalysis. Furthermore, morbidity is of great concern to patients (4). Dose effects could be important in properly interpreting the results of randomized trials on albumin (5). In many of these trials, although albumin was ostensibly compared with crystalloid or no albumin, in fact, the control group received concomitant albumin as part of the study fluid regimen. A common scenario was randomization of patients to receive albumin vs. crystalloid or no albumin intraoperatively, whereas both groups received albumin postoperatively, or vice versa. Not infrequently, the control group received albumin in the form of albumincontaining blood products, as well as purified albumin. Thus, many trials actually compared albumin with a lower dose of albumin, and in some cases, the control dose was fairly large. Obviously, the likelihood of detecting between-group differences in outcome would depend heavily on the relative magnitude of the control group albumin dose.
We report here the results of a metaanalysis focused on morbidity in randomized trials of albumin. This meta-analysis fully accounts for control group albumin dose.
MATERIALS AND METHODS
Inclusion Criteria. Trials were eligible for inclusion if they involved acutely ill hospitalized patients randomly assigned to receive albumin or a control regimen of crystalloid, no albumin, or lower-dose albumin and if morbidity data were available. Trials of albumin for the prevention of ovarian hyperstimulation syndrome among otherwise healthy partici-pants in in vitro fertilization programs were not included.
Data Collection. Published and unpublished trials were sought by a variety of methods, as previously described (2). Briefly, these methods included computer searches of MED-LINE, EMBASE, and the Cochrane Library; hand searches of journals and Index Medicus; inquiries with investigators and fluid product suppliers; and perusal of reference lists. No language or time period restrictions were applied. Two investigators independently selected trials and extracted data on an unblinded basis. Differences in interpretation were resolved through discussion. Extracted data consisted of trial design features, patient characteristics, fluid regimen, complications, and dose of albumin. Deaths were scored as complications, and all complications were recorded on an intention-to-treat basis.
Quality Assessment. Trial quality was evaluated by four criteria: blinding, allocation concealment, presence of morbidity as a study endpoint, and individual patient crossover. The potential importance of blinding and allocation concealment in avoiding bias is well recognized (6). Trials specifically designed to assess morbidity, as opposed to those reporting morbidity as an incidental finding, are more likely to have adopted standardized and systematic methods for diagnosing and reporting complications. As discussed elsewhere (2), in a number of trials, individual control group patients crossed over to albumin therapy if their illness was severe or their clinical condition deteriorated. In an intention-to-treat analysis, such crossover could bias outcomes in favor of the control group over the albumin group.
Statistical Analysis. The primary endpoint for the meta-analysis was the incidence of complications, including death. Because individual patients could experience multiple complications, the analysis focused on counts of complications rather than binary outcomes, such as life or death. We combined data across trials using a mixed effects Poisson regression model, with trial as a random effect, group assignment as a fixed effect, and total patients per group as an exposure (offset) variable (7, 8). Stata 8.0 statistical software (Stata, College Station, TX) and the GLLAMM program were used for this purpose (9). The model was used to calculate the risk ratio (RR) for complications and its 95% confidence interval (CI). RR Ͻ1 signifies a lower incidence of complications in the albumin group, whereas RR Ͼ1 favors the control group. Statistically significant effects are indicated by the absence of 1 from the CI, because this means that with 95% probability, the true RR is different from 1 and an RR of 1 signifies no between-group difference in effect. Heterogeneity was assessed by the likelihood ratio test. Publication bias was evaluated by regression of effect size vs. precision (10) using the METABIAS program (11).
Sensitivity analyses were planned a priori on the effects of clinical indication, type of complication, and albumin dose. Such analyses involve the assessment of results after stratification according to variables that might affect outcome. For each trial, the total dose of albumin in grams from all sources during the study period was calculated for both the albumin and control groups, and control group dose was expressed as a percentage of albumin group dose. The contribution of blood products to total albumin dose was calculated using the following albumin concentration values: 4.21 g/dL in whole blood, 1.91 g/dL in packed red blood cells, and 4.09 g/dL in fresh frozen plasma (12).
Support. The study sponsor played no role in the design of the study, the collection, analysis, and interpretation of data, the writing of the manuscript, or the decision to submit the article for publication.
RESULTS
Included Trials. As summarized in Figure 1 , 85 candidate trials with a total of 4,380 randomized patients were identified (12-97). Morbidity data were not reported and could not be obtained through inquiry for 13 of these trials (17-19, 24, 57, 67, 75, 81, 84, 89, 91, 93, 98) . One trial with reported morbidity data was excluded (33), because the albumin group was subjected to fluid overload, as has been widely recognized (44, 99 -103) . Specifically, in that trial the albumin group received a mean of 44.9 L of total fluid, including a mean of 1,142 g of albumin, resulting in supranormal central venous pressure (mean, 18.6 cm H 2 O vs. 10.7 cm H 2 O in the control group) and hyperalbuminemia (mean serum albumin, 5.4 g/dL vs. 2.9 g/dL in the control group). The remaining 71 trials with 3,782 randomized patients, accounting for 86% (3,782/4,380) of the randomized patients in all candidate trials, were included in the meta-analysis. All had been reported in published form. In response to inquiries seeking morbidity data absent from the published reports, the investigators of 12 trials furnished unpublished data (34, 36, 47, 49, 60, 65, 66, 71, 72, 74, 92, 96) .
Forty of the 71 included trials involved surgery or trauma, four burns, five hypoalbuminemia, nine high-risk neonates, six ascites, and seven other indications (Table 1 ). In the other indications category were two trials each of acute respiratory distress syndrome (32, 45) and hyperbilirubinemia (15, 36) and one each of septic and hypovolemic shock (44) , acute ischemic stroke (68) , and vascular leak syndrome (79) . The median number of randomized patients per included trial was 36, with an interquartile range (IQR) of 20 -68. Infants were the subjects of 12 trials (13-15, 20, 23, 36, 69, 74, 87, 92, 96, 97) , children of one (12), and adults of 55. Age in three trials was unspecified (58, 64, 88) . Median patient age in the adult trials was 57 yrs (IQR, 48 -62 yrs). The median duration of follow-up for all included trials was 4 days (IQR, 1-15 days).
Morbidity. A total of 3,287 complica- patients with intestinal edema (jejunal water fraction Ͼ4.5 g H 2 O/g tissue dry weight) estimated from reported continuous data using z scores; e patients received acute albumin therapy during hospitalization followed by long-term outpatient albumin therapy after discharge. Only data pertaining to acute therapy extracted for meta-analysis.
Overall Effect. Overall morbidity was significantly lower in albumin recipients than control patients (RR, 0.92; CI, 0.86 -0.98), as shown in Figure 2 . The number needed to treat with albumin to avoid one complication was 44 patients. There was significant between-trial heterogeneity in overall morbidity (p Ͻ .005), indicating the appropriateness of random effects modeling and of investigating potential sources of heterogeneity, such as clinical indication, complication type, and dose. There was no evidence of publication bias by test for zero intercept in regression of effect size vs. precision (p ϭ .28). The slope of the regression line was 0.0127 (CI, Ϫ0.205 to 0.230) and the intercept was Ϫ0.422 (CI, Ϫ1.20 to 0.355). Additionally, no publication bias was apparent by funnel plot (Fig. 3) . Year of study publication, when included as a covariate in the mixed effects regression model, was not significantly predictive of morbidity (p ϭ .91) and had no effect on RR, which remained at 0.92 (CI, 0.86 -0.98). Thus, there was no evidence of temporal drift in treatment effects among the included trials. With inclusion of either within-trial mortality risk difference or within-trial control group mortality rate as a covariate, pooled RR for morbidity was 0.92 (CI, 0.86 -0.99). Therefore, the protective effect of albumin with respect to morbidity could neither be explained by higher mortality in the albumin group (104) nor by differences in severity of illness as reflected by underlying patient mortality risk (105) .
Clinical Indications. A trend toward reduced morbidity could be discerned in trials of burns, hypoalbuminemia, and high-risk neonates, whereas for the ascites trials, there was a statistically significant morbidity benefit of albumin (Fig. 2) . No effect was demonstrable among trials of surgery or trauma and other indications.
Complication Types. The most frequently documented individual types of complications in the cardiovascular category were myocardial infarction, cardiac insufficiency, hypotension, hemorrhage, congestive heart failure, arrhythmia, cerebrovascular accident, shock, neurocognitive impairment, cardiac arrest, and deep vein thrombosis; in the gastrointestinal category: gastrointestinal bleeding, necrotizing enterocolitis, and diarrhea; in the hepatic category: liver failure and hepatic encephalopathy; in the infectious category: sepsis, wound infection, and urinary tract infection; in the renal category: renal failure/dysfunction and hyponatremia; in the respiratory category: respiratory failure, pneumonia, pulmonary edema, pleural effusion, atelectasis, and pulmonary embolism; and in the other category: operation/reoperation, wound dehiscence, allergic reaction, decubitus ulcer, and fistula. The only statistically significant effect with respect to complication type was an albumin-mediated reduction in renal, hepatic, and gastrointestinal complications (Fig. 4) .
Trial Quality. By all four evaluated criteria, RR was smaller among higherthan lower-quality trials (Table 2) . Albumin significantly decreased morbidity in trials with blinding, adequate allocation concealment, a morbidity endpoint, and the absence of crossover.
Control Dose. In four trials, patients were randomized to receive a higher vs. a lower dose of albumin (12, 48, 80, 95) . In 35 additional trials, the randomized control regimen consisted of crystalloid or no albumin. However, control group patients in these trials nevertheless received albumin in some form during the study period. For all trials in which the control group received albumin, the median control group dose expressed as a percentage of the albumin group dose was 21% (IQR, 9 -57%). A significant overall relationship was found to exist between control group albumin dose and the incidence of complications (p ϭ .002 by test of interaction). For most comparisons of the clinical indications, complication types, and total morbidity shown in Fig. 4 , the incidence of complications was significantly reduced by albumin as compared with no albumin. When albumin was compared with a control regimen of low-dose albumin, there was generally a more modest protective effect, which attained statistical significance only in comparisons involving indications other than surgery or trauma (p ϭ .046), renal, hepatic, and gastrointestinal complications (p ϭ .042), and all trials combined (p ϭ .047). RR was Ͼ1 for all comparisons but one . Effect of control group albumin dose on risk ratio (RR) for morbidity. Trials were categorized as involving low-dose albumin in the control group (i.e., Յ25% of the albumin group dose), moderate-dose albumin (i.e., Ͼ25% of the albumin group dose), or no albumin. CI, confidence interval; GI, gastrointestinal.
between albumin and moderate-dose control albumin. These observations suggest that moderate doses of albumin may be more beneficial than no albumin and than either low or high doses.
DISCUSSION
In this meta-analysis of 71 randomized trials among acutely ill hospitalized patients, we found that albumin significantly diminished overall morbidity. The morbidity benefit of albumin was consistently more pronounced in higherquality trials. Concomitant albumin in the control group proved to be an important predictor of treatment effect. The use of albumin in the control group would tend to offset any cost advantage of the control fluid regimen.
If attention is focused exclusively on trials with no albumin in the control group, the RR was Ͻ1 for all comparisons of clinical indications, complication types, and overall morbidity displayed in Figure 4 . The effect was statistically significant for five of the eight comparisons, namely, surgery or trauma, other indications, cardiovascular, renal, hepatic and gastrointestinal complications, and overall morbidity. The RR for death was 0.96 (CI, 0.75-1.23) in the 28 trials with no albumin in the control group.
Conversely, in trials with moderatedose albumin in the control group, the RR was Ͼ1 for nearly all comparisons. Our results are, therefore, consistent with a biphasic dose-response relationship between albumin and morbidity, in which complications are minimized by moderate doses of albumin as compared either with no albumin or with low and high doses. Such a biphasic effect of albumin dose on mortality has been shown in a rodent model of shock induced by intestinal ischemia (106) .
Morbidity has served as a frequent endpoint for meta-analyses (107-109).
Despite its greater sensitivity, morbidity does not constitute a single homogeneous, easily diagnosed outcome, as does mortality. Complications can differ not only by type but by severity, and in randomized clinical trials, the approaches to diagnosing and reporting complications have varied. Nevertheless, we found that among those trials with a morbidity endpoint, i.e., those applying more stringent standards for diagnosing and reporting complications, albumin exerted a significant protective effect.
Bias in the inclusion of data is a recognized threat to the validity of a metaanalysis (110) . Our meta-analysis included three important safeguards against such bias: a large data sample, nonselectivity, and transparency. We employed rigorous search methodology designed to capture the totality of pertinent evidence, and indeed, ours is by a wide margin the largest quantitative metaanalysis of randomized trials thus far in the field of fluid management. Failure to assemble the entirety of the available data creates the danger of sampling bias. As elsewhere detailed (111) for instance, reliance by the Cochrane investigators on a small biased subset of available randomized trial data was sufficient to explain the disparity in results between their 1998 meta-analysis of survival after albumin administration (1) and the more comprehensive 2001 meta-analysis of Wilkes and Navickis (2). The 2001 metaanalysis has now been confirmed by the large-scale Saline versus Albumin Fluid Evaluation randomized trial (3), which has also provided support for the mortality findings in the present meta-analysis.
We adopted broad trial selection criteria and took "all comers." Only a single trial (33) was excluded-with very strong justification from physiologic data and published expert opinion (44, 99 -103) . There were no other exclusions of eligible trials whatever. Transparency is provided by the data in Table 1 , which are derived from published sources and show exactly how we scored complications for each trial so that other investigators can replicate our results.
What mechanisms might account for reduced morbidity in albumin recipients? Voluminous epidemiologic data indicate that endogenous serum albumin plays a direct protective role in averting morbidity and mortality (5). One obvious potential protective mechanism of administered albumin would be in maintaining colloid oncotic pressure and preventing fluid imbalance, for example, in the form of pulmonary edema (112) . Non-oncotic properties of albumin may also favorably affect outcomes (113) . This is the first systematic review of morbidity in broad populations of acutely ill hospitalized patients receiving human albumin. It has been contended that there is no evidence to support the widespread use of albumin (114) . Our metaanalysis suggests otherwise, because albumin significantly reduced overall morbidity. With proper accounting for dose, the beneficial effect of albumin on morbidity was substantially stronger and more pervasive.
We have examined the effect of albumin on morbidity very broadly. Our overall findings would by no means necessarily apply to every particular clinical situation. Further studies are needed to delineate the optimal role for albumin, if any, in specific settings and patient populations. It would appear that dose should be a major focus of such investigations and that reports of future randomized trials should very clearly specify the relative doses of albumin received by each study group. Our results also underscore the value of carefully investigating effect size modifiers such as dose when conducting meta-analyses.
CONCLUSIONS
Albumin reduces morbidity in broad populations of acutely ill hospitalized patients. In many randomized trials, this effect has been masked by concomitant albumin administered to the control group. 
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